In vivo and in vitro characterization of CCK8 bearing a histidine-based chelator labeled with 99mTc-tricarbonyl

Luca D. D'Andrea, Irma Testa, Maria Rosaria Panico, Rossella Di Stasi, Corradina Caracò, Laura Tarallo, Claudio Arra, Antonio Barbieri, Alessandra Romanelli, Luigi Aloj

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The development of receptor targeting radiolabeled ligands has gained much interest in recent years for diagnostic and therapeutic applications in nuclear medicine. Cholecystokinin (CCK) receptors have been shown to be overexpressed in a subset of neuroendocrine and other tumors. We are evaluating binding and biodistribution properties of a CCK8 peptide derivative labeled with 99mTc(I)-tricarbonyl. The CCK8 peptide was modified at its N-terminus by adding to its N-terminus two lysine-histidine modules (KH), where histidine is coupled to the side chain of the lysine ((KH)2-CCK8). 99mTc(I)-tricarbonyl was generated with the IsoLinkTM kit. A431 cells stably transfected with a cDNA encoding for the human CCK2 receptor were utilized to determine binding affinity, internalization, and retention of the labeled peptide, in comparison with wild-type A431 cells. A nude mouse tumor model was obtained by generating A431-CCK2R and A431-control tumors in opposite flanks of the animals. High specific activity labeling with 99mTc was achieved. In A431-CCK2R cells, specific saturable binding was observed as well as evident internalization of the radiolabeled peptide after binding. Biodistribution experiments showed rapid, specific localization of (KH)2-CCK8 on A431-CCK2R xenografts compared with control tumors, although absolute uptake values were not markedly higher compared with background activity. Clearance of unbound radioactivity was both urinary and hepatobiliary. In imaging experiments, while targeting to CCK2R positive tumors could be appreciated, there was poor contrast between target and nontarget areas. (KH)2-CCK8 shows adequate in vitro and in vivo properties for CCK2R targeting although improvement of biodistribution warrant further development.

Original languageEnglish
Pages (from-to)707-712
Number of pages6
JournalBiopolymers
Volume90
Issue number5
DOIs
Publication statusPublished - 2008

Fingerprint

Bearings (structural)
Chelating Agents
Histidine
Tumors
Peptides
Lysine
Neoplasms
Cholecystokinin B Receptor
Cholecystokinin Receptors
Neuroendocrine Tumors
Nuclear Medicine
Nuclear medicine
Heterografts
Nude Mice
Radioactivity
Complementary DNA
Labeling
Ligands
Animals
Experiments

Keywords

  • Carbonyl
  • Cholecystokinin receptors
  • Imaging
  • Organometallic complexes
  • Radiopeptide
  • Technetium

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Biomaterials
  • Organic Chemistry

Cite this

In vivo and in vitro characterization of CCK8 bearing a histidine-based chelator labeled with 99mTc-tricarbonyl. / D'Andrea, Luca D.; Testa, Irma; Panico, Maria Rosaria; Di Stasi, Rossella; Caracò, Corradina; Tarallo, Laura; Arra, Claudio; Barbieri, Antonio; Romanelli, Alessandra; Aloj, Luigi.

In: Biopolymers, Vol. 90, No. 5, 2008, p. 707-712.

Research output: Contribution to journalArticle

D'Andrea, Luca D. ; Testa, Irma ; Panico, Maria Rosaria ; Di Stasi, Rossella ; Caracò, Corradina ; Tarallo, Laura ; Arra, Claudio ; Barbieri, Antonio ; Romanelli, Alessandra ; Aloj, Luigi. / In vivo and in vitro characterization of CCK8 bearing a histidine-based chelator labeled with 99mTc-tricarbonyl. In: Biopolymers. 2008 ; Vol. 90, No. 5. pp. 707-712.
@article{6b4acc35a9ba4db995826041974cffe6,
title = "In vivo and in vitro characterization of CCK8 bearing a histidine-based chelator labeled with 99mTc-tricarbonyl",
abstract = "The development of receptor targeting radiolabeled ligands has gained much interest in recent years for diagnostic and therapeutic applications in nuclear medicine. Cholecystokinin (CCK) receptors have been shown to be overexpressed in a subset of neuroendocrine and other tumors. We are evaluating binding and biodistribution properties of a CCK8 peptide derivative labeled with 99mTc(I)-tricarbonyl. The CCK8 peptide was modified at its N-terminus by adding to its N-terminus two lysine-histidine modules (KH), where histidine is coupled to the side chain of the lysine ((KH)2-CCK8). 99mTc(I)-tricarbonyl was generated with the IsoLinkTM kit. A431 cells stably transfected with a cDNA encoding for the human CCK2 receptor were utilized to determine binding affinity, internalization, and retention of the labeled peptide, in comparison with wild-type A431 cells. A nude mouse tumor model was obtained by generating A431-CCK2R and A431-control tumors in opposite flanks of the animals. High specific activity labeling with 99mTc was achieved. In A431-CCK2R cells, specific saturable binding was observed as well as evident internalization of the radiolabeled peptide after binding. Biodistribution experiments showed rapid, specific localization of (KH)2-CCK8 on A431-CCK2R xenografts compared with control tumors, although absolute uptake values were not markedly higher compared with background activity. Clearance of unbound radioactivity was both urinary and hepatobiliary. In imaging experiments, while targeting to CCK2R positive tumors could be appreciated, there was poor contrast between target and nontarget areas. (KH)2-CCK8 shows adequate in vitro and in vivo properties for CCK2R targeting although improvement of biodistribution warrant further development.",
keywords = "Carbonyl, Cholecystokinin receptors, Imaging, Organometallic complexes, Radiopeptide, Technetium",
author = "D'Andrea, {Luca D.} and Irma Testa and Panico, {Maria Rosaria} and {Di Stasi}, Rossella and Corradina Carac{\`o} and Laura Tarallo and Claudio Arra and Antonio Barbieri and Alessandra Romanelli and Luigi Aloj",
year = "2008",
doi = "10.1002/bip.21041",
language = "English",
volume = "90",
pages = "707--712",
journal = "Biopolymers",
issn = "0006-3525",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - In vivo and in vitro characterization of CCK8 bearing a histidine-based chelator labeled with 99mTc-tricarbonyl

AU - D'Andrea, Luca D.

AU - Testa, Irma

AU - Panico, Maria Rosaria

AU - Di Stasi, Rossella

AU - Caracò, Corradina

AU - Tarallo, Laura

AU - Arra, Claudio

AU - Barbieri, Antonio

AU - Romanelli, Alessandra

AU - Aloj, Luigi

PY - 2008

Y1 - 2008

N2 - The development of receptor targeting radiolabeled ligands has gained much interest in recent years for diagnostic and therapeutic applications in nuclear medicine. Cholecystokinin (CCK) receptors have been shown to be overexpressed in a subset of neuroendocrine and other tumors. We are evaluating binding and biodistribution properties of a CCK8 peptide derivative labeled with 99mTc(I)-tricarbonyl. The CCK8 peptide was modified at its N-terminus by adding to its N-terminus two lysine-histidine modules (KH), where histidine is coupled to the side chain of the lysine ((KH)2-CCK8). 99mTc(I)-tricarbonyl was generated with the IsoLinkTM kit. A431 cells stably transfected with a cDNA encoding for the human CCK2 receptor were utilized to determine binding affinity, internalization, and retention of the labeled peptide, in comparison with wild-type A431 cells. A nude mouse tumor model was obtained by generating A431-CCK2R and A431-control tumors in opposite flanks of the animals. High specific activity labeling with 99mTc was achieved. In A431-CCK2R cells, specific saturable binding was observed as well as evident internalization of the radiolabeled peptide after binding. Biodistribution experiments showed rapid, specific localization of (KH)2-CCK8 on A431-CCK2R xenografts compared with control tumors, although absolute uptake values were not markedly higher compared with background activity. Clearance of unbound radioactivity was both urinary and hepatobiliary. In imaging experiments, while targeting to CCK2R positive tumors could be appreciated, there was poor contrast between target and nontarget areas. (KH)2-CCK8 shows adequate in vitro and in vivo properties for CCK2R targeting although improvement of biodistribution warrant further development.

AB - The development of receptor targeting radiolabeled ligands has gained much interest in recent years for diagnostic and therapeutic applications in nuclear medicine. Cholecystokinin (CCK) receptors have been shown to be overexpressed in a subset of neuroendocrine and other tumors. We are evaluating binding and biodistribution properties of a CCK8 peptide derivative labeled with 99mTc(I)-tricarbonyl. The CCK8 peptide was modified at its N-terminus by adding to its N-terminus two lysine-histidine modules (KH), where histidine is coupled to the side chain of the lysine ((KH)2-CCK8). 99mTc(I)-tricarbonyl was generated with the IsoLinkTM kit. A431 cells stably transfected with a cDNA encoding for the human CCK2 receptor were utilized to determine binding affinity, internalization, and retention of the labeled peptide, in comparison with wild-type A431 cells. A nude mouse tumor model was obtained by generating A431-CCK2R and A431-control tumors in opposite flanks of the animals. High specific activity labeling with 99mTc was achieved. In A431-CCK2R cells, specific saturable binding was observed as well as evident internalization of the radiolabeled peptide after binding. Biodistribution experiments showed rapid, specific localization of (KH)2-CCK8 on A431-CCK2R xenografts compared with control tumors, although absolute uptake values were not markedly higher compared with background activity. Clearance of unbound radioactivity was both urinary and hepatobiliary. In imaging experiments, while targeting to CCK2R positive tumors could be appreciated, there was poor contrast between target and nontarget areas. (KH)2-CCK8 shows adequate in vitro and in vivo properties for CCK2R targeting although improvement of biodistribution warrant further development.

KW - Carbonyl

KW - Cholecystokinin receptors

KW - Imaging

KW - Organometallic complexes

KW - Radiopeptide

KW - Technetium

UR - http://www.scopus.com/inward/record.url?scp=58149179423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149179423&partnerID=8YFLogxK

U2 - 10.1002/bip.21041

DO - 10.1002/bip.21041

M3 - Article

VL - 90

SP - 707

EP - 712

JO - Biopolymers

JF - Biopolymers

SN - 0006-3525

IS - 5

ER -